Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mach7 Technologies ( (AU:M7T) ) has provided an announcement.
Mach7 Technologies has disclosed a change in the holdings of director Robert Bazzani, detailing an increase in his indirect interest in the company’s fully paid ordinary shares. The additional shares were acquired through on-market purchases across three transactions in late March 2026 at prices ranging from $0.2700 to $0.2750 per share.
Following the trades, Bazzani’s indirect holdings now comprise existing shares and options via Doromax Pty Ltd, as well as 73,141 fully paid ordinary shares held through Birdsvale Pty Ltd. The company noted that these acquisitions did not occur during a closed trading period, indicating routine portfolio adjustment rather than an exceptional trading circumstance.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.25 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
More about Mach7 Technologies
Mach7 Technologies Limited is an Australian-listed company operating in the technology sector. The firm is focused on healthcare imaging and data management solutions, providing software platforms that help hospitals and health systems store, access, and share medical images and related clinical information.
YTD Price Performance: -57.72%
Average Trading Volume: 256,252
Technical Sentiment Signal: Sell
Current Market Cap: A$61.1M
See more data about M7T stock on TipRanks’ Stock Analysis page.